SynthesisInflammation research : official journal of the European Histamine Research Society ... [et al.]2012
Association of IL23R polymorphisms with psoriasis and psoriatic arthritis: a meta-analysis.
Synthesis in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Four polymorphisms of VEGF (+405C>G, -460T>C, -2578C>A, and -1154G>A) in susceptibility to psoriasis: a meta-analysis.DNA and cell biology · 2014Pooled it
- In Silico Identification and Structural Characterization of High-Risk Missense SNVs in the HumanGenes · 2026Article
- Genetic Association Study ofLife (Basel, Switzerland) · 2026Article
- Etiopathogenesis of Psoriasis from Genetic Perspective: An updated Review.Current genomics · 2022Review
- The Inflammatory Factor SNP May Serve as a Promising Biomarker for Acitretin to Alleviate Secondary Failure of Response to TNF-a Monoclonal Antibodies in Psoriasis.Frontiers in pharmacology · 2022Article
- Cognitive Process of Psoriasis and Its Comorbidities: From Epidemiology to Genetics.Frontiers in genetics · 2021Review
- Juvenile Spondyloarthritis: What More Do We Know About HLA-B27, Enthesitis, and New Bone Formation?Frontiers in medicine · 2021Review
- Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis.Journal of personalized medicine · 2020Article
- Evaluation of interleukin-23 receptor (IL-23R) gene polymorphisms and serum IL-23 levels in patients with psoriasisTurkish journal of medical sciences · 2019Article
- Genetic polymorphisms associated with psoriasis and development of psoriatic arthritis in patients with psoriasis.PloS one · 2018Article
- Article
- The Clinical and Cost Effectiveness of Ustekinumab for the Treatment of Psoriatic Arthritis: A Critique of the Evidence.PharmacoEconomics · 2016Review
- IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases.Nature medicine · 2015Review
- Preclinical development of AMG 139, a human antibody specifically targeting IL-23.British journal of pharmacology · 2015Article
- Worldwide population distribution of the common LCE3C-LCE3B deletion associated with psoriasis and other autoimmune disorders.BMC genomics · 2013Article
- Association between polymorphisms of the IL-23R gene and allergic rhinitis in a Chinese Han population.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe association of variants in the IL23R gene with psoriasis and psoriatic arthritis (PsA) is a robust genetic finding
objectivesTo assess whether combined evidence shows the association between IL23R polymorphisms and susceptibility to psoriasis/PsA.
methodsWe conducted a meta-analysis to examine the association between the IL23R rs11209026 (Q381R), rs7530511 (L310P), and rs2201841 polymorphisms and psoriasis/PsA.
resultsThirteen articles met the inclusion criteria and contributed data to the meta-analysis. For rs11209026, the odds ratios (ORs) of minor alleles for psoriasis and PsA were 0.616 [95 % confidence interval (CI) 0.563-0.674] and 0.630 (95 % CI 0.524-0.757), respectively. For rs7530511, the pooled ORs were 0.820 (95 % CI 0.764-0.879) for psoriasis and 0.875 (95 % CI 0.766-1.000) for PsA; for rs2201841 the OR was 1.121 (95 % CI 1.031-1.219) for psoriasis. In genotypic analysis, the association of rs11209026 (A) and rs7530511 (T) were compatible with the dominant model (P < 0.0001, P = 0.001 respectively). The overall ORs for GG vs. AA (OR 1.339; 95 % CI 1.151-1.558), GG vs. GA (OR 1.143; 95 % CI 1.004-1.300), dominant (OR 1.226; 95 % CI 1.143-1.316), and recessive (OR 1.254; 95 % CI 1.115-1.411) models of rs2201841 were all significantly increased in psoriasis. No publication bias was present.
conclusionsOur results demonstrate a significant association between IL23R gene polymorphisms and psoriasis/PsA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.